{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:07:03Z","timestamp":1791958023802,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atenci\u00f3n Primaria"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.aprim.2024.103143","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T09:53:26Z","timestamp":1732010006000},"page":"103143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tratamiento farmacol\u00f3gico de la diabetes mellitus tipo 2"],"prefix":"10.1016","volume":"57","author":[{"given":"Francisco Javier","family":"Garc\u00eda Soid\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Riveiro Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.aprim.2024.103143_bib0150","first-page":"S1","article-title":"Standards of Care in Diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care."},{"key":"10.1016\/j.aprim.2024.103143_bib0155","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes","volume":"352","year":"1998","journal-title":"Lancet."},{"key":"10.1016\/j.aprim.2024.103143_bib0160","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet."},{"key":"10.1016\/j.aprim.2024.103143_bib0165","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet."},{"key":"10.1016\/j.aprim.2024.103143_bib0170","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA."},{"key":"10.1016\/j.aprim.2024.103143_bib0175","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspectivepioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet."},{"key":"10.1016\/j.aprim.2024.103143_bib0180","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/STROKEAHA.116.013977","article-title":"Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis","volume":"48","author":"Lee","year":"2017","journal-title":"Stroke."},{"key":"10.1016\/j.aprim.2024.103143_bib0185","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0195-668X(03)00468-8","article-title":"Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies","volume":"25","author":"Hanefeld","year":"2004","journal-title":"Eur Heart J."},{"key":"10.1016\/j.aprim.2024.103143_bib0190","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.107.720847","article-title":"Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascu-lar risk: a population study of 3.3 million people","volume":"117","author":"Schramm","year":"2008","journal-title":"Circulation."},{"key":"10.1016\/j.aprim.2024.103143_bib0195","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aprim.2024.103143_bib0200","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aprim.2024.103143_bib0205","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aprim.2024.103143_bib0210","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA."},{"key":"10.1016\/j.aprim.2024.103143_bib0215","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aprim.2024.103143_bib0220","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outco-mes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"issue":"10193","key":"10.1016\/j.aprim.2024.103143_bib0225","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.aprim.2024.103143_bib0230","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aprim.2024.103143_bib0235","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aprim.2024.103143_bib0240","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.aprim.2024.103143_bib0245","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12933-024-02154-w","article-title":"The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis","volume":"23","author":"Ali","year":"2024","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.aprim.2024.103143_bib0250","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis","volume":"65","author":"Karagiannis","year":"2022","journal-title":"Diabetologia."},{"key":"10.1016\/j.aprim.2024.103143_bib0255","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aprim.2024.103143_bib0260","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aprim.2024.103143_bib0265","doi-asserted-by":"crossref","first-page":"37","DOI":"10.52102\/diabet\/pract.2023.2.art2","article-title":"Algoritmo de tratamiento de la diabetes mellitus tipo 2. RedGDPS 2023","volume":"14","author":"Garc\u00eda-Soid\u00e1n","year":"2023","journal-title":"Diabetes pr\u00e1ctica."},{"key":"10.1016\/j.aprim.2024.103143_bib0270","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1111\/dom.13847","article-title":"GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials","volume":"21","author":"Giugliano","year":"2019","journal-title":"Diabetes Obes Metab."},{"issue":"10365","key":"10.1016\/j.aprim.2024.103143_bib0275","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet."},{"key":"10.1016\/j.aprim.2024.103143_bib0280","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.aprim.2024.103143_bib0285","first-page":"832","article-title":"Deprescribing antihypergly-cemic agents in older persons: Evidence-based clinical practice guideline","volume":"63","author":"Farrell","year":"2017","journal-title":"Can Fam Physician."},{"key":"10.1016\/j.aprim.2024.103143_bib0290","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/dom.14008","article-title":"Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis","volume":"22","author":"Hussein","year":"2020","journal-title":"Diabetes Obes Metab."}],"container-title":["Atenci\u00f3n Primaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0212656724002853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0212656724002853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T18:42:03Z","timestamp":1757961723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0212656724002853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0212656724002853"],"URL":"https:\/\/doi.org\/10.1016\/j.aprim.2024.103143","relation":{},"ISSN":["0212-6567"],"issn-type":[{"value":"0212-6567","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tratamiento farmacol\u00f3gico de la diabetes mellitus tipo 2","name":"articletitle","label":"Article Title"},{"value":"Atenci\u00f3n Primaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aprim.2024.103143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"103143"}}